Mylan CEO Heather Bresch on Wednesday announced an early Christmas present of sorts for users of the company’s EpiPen, saying it planned to launch a lower-cost but identical generic version of the allergy injector during the first half of December.

Mylan had promised back in August to bring the generic to market this year amid growing public backlash and legislative outrage over the soaring cost of the potentially life-saving medication.

The generic version will have a list price of $300 per two-pack vs. more than $600 for a pair of EpiPens. The company said wholesale orders for the brand-name device slowed during the third quarter in anticipation of the new product.

The announcement of a launch date came as Mylan reported it lost $119.8 million, or 23 cents per share, in the third quarter reflecting a charge for the proposed $465 million settlement with the U.S. Justice Department for overcharging Medicaid for the EpiPen. The settlement, announced by Mylan in October, did not include an admission of wrongdoing.

Advertise with us

The third-quarter loss compared with a year-ago profit of $428.6 million, or 83 cents per share.

Excluding the Justice Department settlement and other items, adjusted profits were $1.38 per share, down 3 percent from a year earlier and below Wall Street estimates of $1.45 per share.

Revenue for the three months ended Sept. 30 was $3.06 billion, up 13 percent from $2.7 billion.

Results were released after the close of the stock market Wednesday. Shares closed at $38.92, up $1.81, or about 5 percent. The stock has fallen about 28 percent since the start of the year and some 17 percent since Aug. 1, before the EpiPen scandal erupted.

Mylan chief financial officer Kenneth Parks told analysts in a conference call Wednesday that the company continues to work with the government to finalize the Medicaid settlement, which has come under fire from legislators for being too soft on Mylan.

Advertise with us

The U.S. Senate Judiciary Committee has set a hearing for Nov. 30 to scrutinize the deal.

Mylan has its operations base in Cecil.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.